{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-158409","form_type":"8-K","ticker":"WAT","cik":"0001000697","company_name":"WATERS CORP /DE/","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.100187+00:00","generated_at":"2026-05-18T06:35:44.541430+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Waters to combine with BD's Biosciences & Diagnostic Solutions in $17.5B deal","bullets":["Deal valued at ~$17.5B; Waters shareholders own ~60.8%, BD shareholders ~39.2% of combined co.","Pro forma 2025 revenue ~$6.5B, adjusted EBITDA ~$2.0B; expected accretive to adj EPS in Y1.","Targets mid-to-high single-digit revenue growth and mid-teens adj EPS growth annually 2025-2030.","Anticipates ~$345M annualized EBITDA synergies by 2030: $200M cost by Y3, $290M revenue by Y5.","Closing expected around end of Q1 2026, subject to regulatory approvals and Waters shareholder vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-158409","json":"https://secwatch.observer/filing/0001193125-25-158409.json","markdown":"https://secwatch.observer/filing/0001193125-25-158409.md","text":"https://secwatch.observer/filing/0001193125-25-158409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000697/000119312525158409/0001193125-25-158409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000697/000119312525158409/d935060d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:35:44.541430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}